Down-regulation of apoptosis-related bcl-2 but not bcl-x(L) or bax proteins in multidrug-resistant MCF-7/Adr human breast cancer cells

International Journal of Cancer

Volumn 67, Issue 5, 1996, Pages 608-614

  Ogretmen, Besim ^a   Safa, Ahmad R ^a,b  

^a UNIVERSITY OF CHICAGO   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOHEXIMIDE; CYCLOSPORIN A; DOXORUBICIN; ETOPOSIDE; ONCOPROTEIN; PACLITAXEL; PROTEIN BCL 2; VERAPAMIL; VINCRISTINE;

APOPTOSIS; ARTICLE; BREAST CANCER; CELL STRAIN MCF 7; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BASE SEQUENCE; BCL-2-ASSOCIATED X PROTEIN; BCL-X PROTEIN; BREAST NEOPLASMS; CYCLOSPORINE; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; ETOPOSIDE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MOLECULAR SEQUENCE DATA; PACLITAXEL; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, MESSENGER; TUMOR CELLS, CULTURED; VERAPAMIL; VINCRISTINE;

EID: 0029782288     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19960904)67:5<608::AID-IJC3>3.0.CO;2-Y     Document Type: Article

References (28)

1. BLAGOSKLONNY, M.V., SCHULTE, T.W., NGUYEN, P., MIMNAUGH, E.G., TREPEL, J. and NECKERS, L., Taxol induction of p21WAF1 and p53 requires c-raf-1. Cancer Res., 55, 4623-4626 (1995).
2. BOISE, L.H., GONZALES-GARCIA, M., POSTEMA, C.E., DING, L., LINSTEN, T., TURKA, L.A., MAO, X., NUNEZ, G. and THOMPSON, C.B., bcl-x, a bcl-2 related gene that functions as a dominant regulator of apoptotic cell death. Cell, 74, 597-608 (1993).
3. CAMPOS, L., ROUAULT, J.P., SABIDO, O., ORIOL, P., ROUBI, N., VASSELON, C., ARCHIMAUD, E., MAGAUD, J.P. and GUYOTAT, D., High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood, 81, 3091-3096 (1993).
4. 1 is expressed in neuroblastoma cells and modulates chemotherapy-induced apoptosis. Cancer Res., 55, 2576-2582 (1995).
5. FAIRCHILD, C.R. and COWAN, K.H., Multidrug resistance: a pleiotropic response to cytotoxic drugs. Int. J. Rad. Oncol. Biol. Phys., 20, 361-367 (1991).
6. FORNARI, F.A., JARVIS, W.D., GRANT, S., ORR, M.S., RANDOLPH, J.K., WHITE, F.K.H., MUMAW, V.R., LOVINGS, E.T., FREEMAN, R.H. and GEWIRTZ, D.A., Induction of differentiation and growth arrest associated with nascent (non-oligosomal) DNA fragmentation and reduced c-myc expression in MCF-7 human breast tumor cells after continuous exposure to a sublethal concentration of doxorubucin. Cell Growth Differentiation, 5, 723-733 (1994).
7. GASPARINI, G., BARBARESCHI, M., DOGLIONI, C., PALMA, P.D., MAURI, F.A., BORACCHI, P., BEVILACQUA, P., CAFFO, O., MOREELI, L., VERDERIO, P., PEZELLA, F. and HARRIS, A.L., Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer. Clin. Cancer Res., 1, 189-198 (1995).
8. HALDAR, S., NEGRINI, M., MONNE, M., SABBIONI, S. and CROCE, C.M., Down-regulation of bcl-2 by p53 in breast cancer cells. Cancer Res., 54, 2095-2097 (1994).
9. JOENSUU, H., PYLKKANEN, L. and TOIKKANEN, S., Bcl-2 protein expression and long-term survival in breast cancer. Amer. J. Pathol., 145, 1191-1198 (1994).
10. KRAJEWSKI, S., KRAJEWSKA, M., SHABAIK, A., WANG, H.G., IRIE, G., FONG, L. and REED, J.C., Immunohistochemical analysis of in vivo patterns of bcl-x expression. Cancer Res., 54, 5501-5507 (1994).
11. 1 can confer a multidrug resistance phenotype. Blood, 86, 1903-1910 (1995).
12. MIYASHITA, T., KRAJEWSKI, S., KRAJEWSKA, M., WANG, H.G., LIN, H.K., LIEBERMANN, D.A., HOFFMAN, B. and REED, J.C., Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene, 9, 1799-1805 (1994).
13. MORROW, C.S., CHIU, J. and COWAN, K.H., Post-transcriptional control of glutathione-S-transferase pi gene expression in human breast cancer cells. J. biol. Chem., 25, 10544-10550 (1992).
14. OGRETMEN, B. and SAFA, A.R., Minipreparation of total RNA for RT-PCR from cultured human cells. BioTechniques, 19, 374-376 (1995).
15. SAFA, A.R., Photoaffinity labelling of the multidrug-resistance-related P-glycoprotein with photoactive analogs of verapamil. Proc. nat. Acad. Sci. (Wash.), 85, 7187-7191 (1988).
16. 125I]iodophenethyl)spiperone binds to specific regions of P-glycopro- tein and another multidrug binding protein, spiperophilin, in human neuroblastoma cells. Biochemistry, 33, 256-265 (1994).
17. SANDSTROM, P.A., TEBBEY, P.W., CLEAVE, V. and BUKKET, T.M., Lipid hydroxyperoxidase induced apoptosis in T cells displaying a HIV-associated glutathione peroxidase deficiency. J. biol. Chem., 269, 798-801 (1994).
18. SCHNEIDER, E., HORTON, J.K., YANG, C.H., NAKAGAWA, M. and COWAN, K.H., Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF-7 cell line selected for etoposide resistance. Cancer Res., 54, 152-158 (1994).
19. SEDLAK, T.W., OLTVAI, Z.N., YANG, E., WANG, K., BOISE, L.H., THOMPSON, C.B. and KORSMEYER, S.J., Multiple bcl-2 family members demonstrate selective dimerizations with bax. Proc. nat. Acad. Sci. (Wash.), 92, 7834-7838 (1995).
20. SINHA, B.K., MIMNAUGH, E.G., RAJAGOPALAN, S. and MEYERS, C.E., Adriamycin activation and oxygen free radical formation in human breast tumor cells: protective role of glutathione peroxidase in adriamycin resistance. Cancer Res., 49, 3844-3848 (1989).
21. s sensitizes MCF-7 cells to chemotherapy-induced apoptosis. Cancer Res., 55, 2507-2510 (1995).
22. TAMAI, I. and SAFA, A.R., Competitive interactions of cyclosporins with the Vinca alkaloid-binding site of P-glycoprotein in multidrug resistant cells. J. biol. Chem., 265, 16509-16513 (1990).
23. VICKERS, P.J., DICKSON, R.B., SHOEMAKER, R. and COWAN, K.H., A multidrug-resistant MCF-7 human breast cancer cell line which exhibits cross-resistance to antiestrogens and hormone-independent tumor growth in vivo. Mol. Endocrinol., 2, 886-892 (1988).
24. VICKERS, P.J., DUFRESNE, M.J. and COWAN, K.H., Relation between cytochrome p450IA1 expression and estrogen receptor content of human breast cancer cells. Mol. Endocrinol., 3, 157-164 (1989).
25. WELLS, W.W., ROCQUE, P.A., XU, D.P., MEYER, E.B., CHARAMELLA, L.J. and DIMITROV, N.V., Ascorbic acid and cell survival of adriamycin resistant and sensitive MCF-7 breast tumor cells. Free Rad. Biol. Med., 18, 699-708 (1995).
26. WOSIKOWSKI, K., REGIS, J.T., ROBEY, R.W., ALVAREZ, M., BUTERS, J.T.M., GUDAS, J.M. and BATES, S.E., Normal p53 status and function despite the development of drug resistance in human breast cancer cells. Cell Growth Differentiation, 6, 1395-1403 (1995).
27. YIN, X.M., OLTVAI, Z.N. and KORSMEYER, S.J., BH1 and BH2 domains of bcl-2 are required for inhibition of apoptosis and heterodimerization with bax. Nature (Lond.), 369, 321-323 (1994).
28. YUNIS, J.J., MAYER, M.G., ARNESEN, M.A., AEPPLI, D.P., OKEN, M.M. and FRIZZERA, G., Bcl-2 and other genomic alterations in the prognosis of large-cell lymphoma. New Engl. J. Med., 320, 1047-1054 (1989).